Pharming Group N.V. (PHAR) — 6-K Filings

6-K Filings (39)

• 6-K Filing — May 7, 2026
• 6-K Filing — May 7, 2026
• 6-K Filing — Apr 16, 2026
• 6-K Filing — Apr 2, 2026
• 6-K Filing — Mar 27, 2026
• Pharming Group N.V. Files 6-K with Press Release — Nov 6, 2025 Risk: low
  Pharming Group N.V. filed a Form 6-K on November 6, 2025, to furnish a press release dated November 6, 2025. The press release is included as Exhibit 99.1 to th
• Pharming Group N.V. Files 6-K with October Press Release — Oct 22, 2025 Risk: low
  Pharming Group N.V. filed a Form 6-K on October 22, 2025, furnishing a press release dated October 20, 2025. The filing is related to the month of October 2025
• Pharming Group N.V. Files Form 6-K — Oct 6, 2025 Risk: low
  Pharming Group N.V. filed a Form 6-K on October 6, 2025, to furnish a press release dated October 6, 2025. The filing does not contain specific financial figure
• Pharming Group N.V. Files 6-K with Press Release — Oct 1, 2025 Risk: low
  Pharming Group N.V. filed a Form 6-K on October 1, 2025, to furnish a press release dated October 1, 2025. The filing itself does not contain specific financial
• Pharming Group N.V. Files 6-K with Press Release — Sep 10, 2025 Risk: low
  Pharming Group N.V. filed a Form 6-K on September 10, 2025, to furnish a press release dated September 10, 2025, as Exhibit 99.1. The filing does not contain sp
• Pharming Group Appoints New Supervisory Board Member — Sep 2, 2025 Risk: low
  Pharming Group N.V. announced on September 2, 2025, the appointment of Kenne as a new member of its Supervisory Board. Kenne brings extensive experience in the
• Pharming Group N.V. Files 6-K for Q2 Results — Jul 31, 2025 Risk: low
  Pharming Group N.V. filed a Form 6-K on July 31, 2025, to furnish a press release regarding its second quarter financial results. The press release, dated July
• Pharming Group to Host Financial Results Webcast — Jun 24, 2025 Risk: low
  Pharming Group N.V. announced on June 24, 2025, that it will host a webcast to discuss its financial results and business updates. The webcast is scheduled for
• Pharming Group N.V. Files 6-K with June Press Release — Jun 11, 2025 Risk: low
  Pharming Group N.V. filed a Form 6-K on June 11, 2025, to furnish a press release dated the same day. The filing is for the month of June 2025 and indicates tha
• Pharming Group N.V. Files 6-K with Press Release — May 8, 2025 Risk: low
  Pharming Group N.V. filed a Form 6-K on May 8, 2025, to furnish a press release dated May 8, 2025. The filing itself does not contain specific financial figures
• Pharming Group N.V. Files 6-K with Press Release — Apr 30, 2025 Risk: low
  Pharming Group N.V. filed a Form 6-K on April 30, 2025, to furnish a press release dated April 30, 2025. The press release, filed as Exhibit 99.1, is the primar
• Pharming Group N.V. Files Form 6-K with Press Release — Apr 25, 2025 Risk: low
  Pharming Group N.V. announced on April 25, 2025, that it is furnishing a press release as Exhibit 99.1 to its Form 6-K filing. The press release details are not
• Pharming Group's Leniolisib Gets CHMP Positive Opinion — Apr 23, 2025 Risk: medium
  Pharming Group N.V. announced on April 23, 2025, that it has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) regardin
• Pharming Group N.V. Reports Q1 2025 Results — Mar 20, 2025 Risk: low
  Pharming Group N.V. announced its first quarter 2025 financial results on March 20, 2025. The company, headquartered in Leiden, The Netherlands, is a pharmaceut
• Pharming Group N.V. Files 6-K with March 13 Press Release — Mar 13, 2025 Risk: low
  Pharming Group N.V. filed a Form 6-K on March 13, 2025, furnishing a press release dated March 13, 2025, as Exhibit 99.1. The filing is for the month of March 2
• Pharming Group N.V. Files Form 6-K — Mar 4, 2025 Risk: low
  Pharming Group N.V. filed a Form 6-K on March 4, 2025, to furnish a press release dated the same day. The filing does not contain specific financial figures or
• Pharming Group N.V. Files 6-K with Press Release — Feb 20, 2025 Risk: low
  Pharming Group N.V. filed a Form 6-K on February 20, 2025, to furnish a press release dated February 20, 2025. The filing is made under the Securities Exchange
• Pharming Group N.V. Files Form 6-K with Press Release — Feb 7, 2025 Risk: low
  Pharming Group N.V. filed a Form 6-K on February 7, 2025, to furnish a press release dated February 7, 2025, as Exhibit 99.1. The filing does not contain specif
• Pharming Group N.V. Files 6-K with Press Release — Jan 21, 2025 Risk: low
  Pharming Group N.V. filed a Form 6-K on January 21, 2025, to furnish a press release dated January 21, 2025, as Exhibit 99.1. The filing does not contain specif
• Pharming Group to Acquire NovaThera for $150M — Dec 16, 2024 Risk: medium
  Pharming Group N.V. announced on December 15, 2024, that it has entered into a definitive agreement to acquire all of the outstanding shares of NovaThera Inc. f
• Pharming Group's C1-INH Deficiency Drug Shows Positive Phase III Results — Dec 11, 2024 Risk: medium
  Pharming Group N.V. announced positive top-line results from its Phase III clinical trial for leniolisib for the treatment of C1 esterase inhibitor deficiency (
• Pharming Group N.V. Files Form 6-K — Oct 24, 2024 Risk: low
  Pharming Group N.V. filed a Form 6-K on October 24, 2024, to furnish a press release dated October 24, 2024. The filing itself does not contain specific financi
• Pharming Group N.V. Files 6-K with Press Release — Oct 10, 2024 Risk: low
  Pharming Group N.V. filed a Form 6-K on October 10, 2024, to furnish a press release dated the same day as Exhibit 99.1. The filing does not contain specific fi
• Pharming Group inks US marketing deal for RUCONEST® — Sep 26, 2024 Risk: low
  Pharming Group N.V. announced on September 26, 2024, that its subsidiary, Pharming Healthcare Inc., has entered into a marketing and distribution agreement with
• Pharming Group N.V. Files 6-K with Press Release — Aug 1, 2024 Risk: low
  Pharming Group N.V. filed a Form 6-K on August 1, 2024, to furnish a press release dated August 1, 2024. The filing itself does not contain detailed financial i
• Pharming Group N.V. Files 6-K with Press Release — May 30, 2024 Risk: low
  Pharming Group N.V. filed a Form 6-K on May 30, 2024, to furnish a press release dated May 30, 2024. The filing itself does not contain specific financial figur
• Pharming Group N.V. Files Form 6-K — May 21, 2024 Risk: low
  Pharming Group N.V. filed a Form 6-K on May 21, 2024, to furnish a press release dated May 21, 2024, as Exhibit 99.1. The filing does not contain specific finan
• Pharming Group N.V. Files Form 6-K with Press Release — May 15, 2024 Risk: low
  Pharming Group N.V. filed a Form 6-K on May 15, 2024, to furnish a press release dated the same day. The press release, filed as Exhibit 99.1, likely contains i
• Pharming Group N.V. Files 6-K with Press Release — May 8, 2024 Risk: low
  Pharming Group N.V. filed a Form 6-K on May 8, 2024, to furnish a press release dated May 8, 2024. The filing itself does not contain specific financial figures
• Pharming Group N.V. Files 6-K with April Press Releases — Apr 25, 2024 Risk: low
  Pharming Group N.V. filed a Form 6-K on April 25, 2024, to furnish press releases dated April 18-19, 2024, as Exhibits 99.1, 99.2, and 99.3. The filing is for t
• Pharming to Acquire Pharming Healthcare for $100M — Apr 24, 2024 Risk: low
  Pharming Group N.V. announced on April 24, 2024, that it has entered into a definitive agreement to acquire all outstanding shares of its subsidiary, Pharming H
• Pharming Group N.V. Files 6-K with Press Release — Apr 8, 2024 Risk: low
  Pharming Group N.V. filed a Form 6-K on April 8, 2024, to furnish a press release dated April 8, 2024, as Exhibit 99.1. The filing does not contain specific fin
• Pharming Group N.V. Files 6-K for Q4 2023 Update — Mar 14, 2024 Risk: low
  Pharming Group N.V. filed a Form 6-K on March 14, 2024, to furnish a press release dated the same day as Exhibit 99.1. The filing does not contain specific fina
• Pharming Ups 2023 Guidance: RUCONEST® Revenue Jumps 10%, Joenja® Hits $18M — Jan 8, 2024
  Pharming Group N.V. announced updated full-year 2023 guidance on January 8, 2024, projecting a significant 10% growth in RUCONEST® revenue, which is much higher

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX